MBio Diagnostics is the innovator of the proprietary LightDeck platform that delivers highly sensitive, on-the-spot results in minutes. We are developing a robust portfolio of IVD tests and we collaborate with commercial, academic and government partners.
Our team consists of high-caliber business people, engineers and scientists with expertise in hardware and software development, assay development and process engineers. Our state-of-the-art facility in Boulder, Colorado includes fully equipped biosafety laboratories for assay development and a cleanroom for cartridge production.
We are developing a portfolio of diagnostic tests for medical settings where lab-quality results are vital in making time-critical decisions.
The LightDeck COVID-19 Total Antibody Test helps to determine if a person had a past infection and potential immunity.
The LightDeck Host-Response Panels measure biomarkers that appear early in acute infections.
This product line includes point-of-care tests for heart attack, heart failure or blood clots.
MBio Diagnostics has built strong relationships with scientists within government agencies, including BARDA, DARPA, NIH and others. We have been awarded more than $25 million in non-dilutive grants to fund feasibility and product development work in host-response and sepsis. We plan to continue to apply for grants to support strategic initiatives.
Our commercial collaborations are matched to the partner’s needs. Typical arrangements include initial funded feasibility programs followed by comprehensive product development and manufacturing supply agreements. We provide engineering and assay development expertise, including migrating existing assays to the LightDeck platform and developing novel assays.
Contact us to explore partnership opportunities.